Skip to main content

Table 2 Model base-case cohort characteristics

From: A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

 

Males (N = 690)

Females (N = 590)

N (% of Total Cohort)

Mean Age (Years)

Mean eGFR (mL/min/ 1.73 m2)

N (% of Total Cohort)

Mean Age (Years)

Mean eGFR (mL/min/ 1.73 m2)

CKD stage G1

222 (17.3%)

33.6

105.9

225 (17.6%)

34.5

105.8

Subclass 1C

89 (7.0%)

37.7

105.0

103 (8.0%)

38.6

102.9

Subclass 1D

83 (6.5%)

33.1

102.9

80 (6.3%)

33.8

107.3

Subclass 1E

50 (3.9%)

27.0

112.4

42 (3.3%)

26.0

109.8

CKD stage G2

318 (24.8%)

39.3

74.5

280 (21.9%)

40.1

75.2

Subclass 1C

126 (9.8%)

41.8

74.7

140 (10.9%)

42.5

75.6

Subclass 1D

123 (9.6%)

39.3

74.7

106 (8.3%)

39.1

74.4

Subclass 1E

69 (5.4%)

34.8

74.0

34 (2.7%)

33.0

76.2

CKD stage G3

150 (11.7%)

41.3

50.8

85 (6.6%)

41.7

52.0

Subclass 1C

37 (2.9%)

44.9

52.1

34 (2.7%)

44.6

52.5

Subclass 1D

66 (5.2%)

41.7

51.7

34 (2.7%)

41.7

51.2

Subclass 1E

47 (3.7%)

37.9

48.5

17 (1.3%)

35.8

52.4

  1. Source: Otsuka, data on file (2018). Analysis of baseline data for 1280 typical, rapidly progressing patients enrolled in TEMPO 3:4, regardless of randomization to treatment or placebo
  2. See Additional file 1: Table S1 for a description of CKD stages according to the KDIGO CKD staging system [20]
  3. CKD Chronic kidney disease, eGFR Estimated glomerular filtration rate